Nass Valley Gardens Inc. Announces It Will File to Launch a Reg A+ Public Offering
WEST PALM BEACH, FL, Feb. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nass Valley Gardens Inc., a Nevada registered...
Month: February 2022
ICU Medical Announces Time of Fourth Quarter 2021 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and...
Shockwave Medical to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
SANTA CLARA, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of...
Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference
ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is...
SomaLogic Provides 2022 Revenue Guidance in Conjunction with Analyst and Investor Meeting
BOULDER, Colo., Feb. 04, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a...
Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom
Company to initiate one Phase 2 trial in rheumatoid arthritis and a second Phase 2 trial in uveitisNEW ORLEANS and...
Surgery Partners, Inc. Announces Fourth Quarter 2021 Earnings Release Date and Conference Call Details
BRENTWOOD, Tenn., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical...
Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction
PDUFA Target Action Date Set for November 30, 2022 FDA is Currently Not Planning to Hold an Advisory Committee Meeting to...
MedMira Provides a Pre-Annual General Meeting Update
HALIFAX, Nova Scotia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting...
IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results
Reports fourth quarter 2021 revenue of $11.9 million, GAAP diluted EPS of $0.31 and non-GAAP diluted EPS of $0.33Announces full-year...
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer,...
Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
VANCOUVER, British Columbia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB:...
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021
Company Ended the Quarter With Cash of Approximately $527.0 MillionNEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq:...
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease
- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b...
HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert
Results to impact ColoAlert profile for FDA submission Provides opportunity for ColoAlert to achieve gold standard status as the premier...
Arcellx Announces Pricing of Initial Public Offering
GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the...
Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4, 2022 Q4 2021 sales growth...
Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4, 2022 Q4 2021 sales growth...
